| Description |
Recombinant Mouse NKG2A&CD94 Protein is expressed from HEK293 with mFc (IgG1) tag at the C-Terminus.It contains Asn98-Ile244(NKG2A)&Ile32-Ile179(CD94). |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
Q9WU31(NKG2A)&O54707(CD94) |
| Target Symbol |
NKG2A&CD94 |
| Synonyms |
CD159a; NKG2A; NKG2-A; CD94; NKG2A&CD94 |
| Species |
Mouse |
| Expression System |
HEK293 |
| Tag |
C-mFc |
| Expression Range |
Asn98-Ile244(NKG2A) & Ile32-Ile179(CD94) |
| Mol. Weight |
The protein has a predicted MW of18.3 kDa (CD94)&43.1 kDa (NKG2A). Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
The ligand-receptor assignment between HLA-G and NKG2A/CD94 is dependent of the amino acid composition in the HLA-G heavy chain. Understanding the biophysical basis of receptor-mediated events that lead to NK cell inhibition would help to remove non-tumor reactive cells and support personalized mild autologous NK cell therapies. |
